Dr Krebs is a Clinical Senior Lecturer in Experimental Cancer Medicine at The University of Manchester and Consultant in Medical Oncology at The Christie NHS Foundation Trust. He completed undergraduate training at University of Leicester and specialty trained in Oncology in Manchester. He obtained his PHD in circulating biomarkers with application to drug development and completed clinical training as a National Institute for Health Research Academic Clinical Lecturer with post-doctoral experience in molecular biology.
Dr Krebs is currently an early-phase clinical trialist focusing on drug development for lung cancer and precision medicine. He has been Principal or Chief Investigator on >40 and co-investigator on >80 international early phase clinical trials across a broad range of novel therapies, including lead investigator on a number of molecular targeted agents now licensed for rare genomic alterations. His translational research focuses on the clinical application of circulating tumour DNA (ctDNA) to guide personalised treatment selection and to monitor treatment response and resistance to novel agents. He is currently leading two national precision medicine initiatives as Chief Investigator to enhance recruitment to precision medicine early phase trials in the UK, including the ctDNA-based TARGET National Precision Medicine program. He is clinical lead for precision medicine within the Manchester Cancer Research Centre, chair of the National Molecular Tumour Board, Cancer Genomics Clinical Lead for the North West Genomic Laboratory Hub and sits on a range of NHS committees in relation to genomics and the national test directory.